The Role of 5-Hydroxyindoleacetic Acid in Neuroendocrine Tumors: The Journey So Far
International Journal of Endocrine Oncology · 2019-09 · 6 (2)
DOI: 10.2217/ije-2019-0001 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Endocrine Oncology, online erschienen am 12.08.2019. Verfasst von Mfon Ewang-Emukowhate und 2 weiteren Autor:innen. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
5-Hydroxyindole acetic acid (5-HIAA) is a surrogate marker for serotonin measurement and one of the first biochemical markers used in neuroendocrine tumors. In this review, we give a brief history of 5-HIAA and its precursor serotonin. We discuss its clinical utility and diagnostic performance in small intestinal neuroendocrine tumor and describe the challenges encountered during its analysis, historically performed in urine. The introduction of blood-based assays will help overcome some of the issues associated with its measurement in urine. The diagnostic performance of serum and plasma 5-HIAA has been shown to be comparable to that of urine 5-HIAA. Thus, analysis in either serum or plasma will provide a practical and convenient alternative to urine.
Zitieren
APA
Ewang-Emukowhate, M., Nair, D., & Caplin, M. (2019). The Role of 5-Hydroxyindoleacetic Acid in Neuroendocrine Tumors: The Journey So Far. International Journal of Endocrine Oncology, 6(2). https://doi.org/10.2217/ije-2019-0001
Vancouver
Ewang-Emukowhate M, Nair D, Caplin M. The Role of 5-Hydroxyindoleacetic Acid in Neuroendocrine Tumors: The Journey So Far. International Journal of Endocrine Oncology. 2019;6(2). doi:10.2217/ije-2019-0001
BibTeX
@article{EwangEmukowhate2019,
author = {Ewang-Emukowhate, Mfon and Nair, Devaki and Caplin, Martyn},
title = {The Role of 5-Hydroxyindoleacetic Acid in Neuroendocrine Tumors: The Journey So Far},
journal = {International Journal of Endocrine Oncology},
year = {2019},
volume = {6},
number = {2},
doi = {10.2217/ije-2019-0001}
}
EUVIMED